Announcements
- Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
- Elicio Therapeutics Announces Proposed Public Offering
- Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
- Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
- Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
- Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
- Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
- Elicio Therapeutics Announces $7.0 Million Private Placement Financing
More ▼
Key statistics
As of last trade, Elicio Therapeutics Inc (9HA:FRA) traded at 4.24, 41.33% above the 52 week low of 3.00 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.18 |
---|---|
High | 4.24 |
Low | 4.18 |
Bid | 3.98 |
Offer | 4.36 |
Previous close | 4.26 |
Average volume | 14.00 |
---|---|
Shares outstanding | 10.72m |
Free float | 7.69m |
P/E (TTM) | -- |
Market cap | 50.28m USD |
EPS (TTM) | -6.63 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 14:29 BST.
More ▼